Management of stable coronary artery disease.
Options for the treatment of multivessel coronary artery disease include medical therapy and revascularization with either coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA). CABG has been shown to prolong survival in patients with left main coronary disease or when at least two of the following factors are present: extensive coronary artery disease, significant ischemia as shown on stress testing and left ventricular dysfunction. In patients with extensive coronary artery disease but normal left ventricular function, either PTCA or CABG may be used initially without adversely affecting rates of survival. However, patients undergoing angioplasty have a higher rate of repeat revascularization procedures than those treated with bypass. The complex interplay of the various risks and benefits of medical therapy, angioplasty or bypass in the treatment of coronary artery disease requires an individualized approach to therapy and careful patient education.
Gutstein
D E
DE
Cardiovascular Institute, Mount Sinai Medical Center, New York, New York, USA.
Fuster
V
V
D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D001026:Coronary Artery Bypass / Q000191:economics; D003327:Coronary Disease / Q000188:drug therapy / Q000191:economics / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D016017:Odds Ratio; D012720:Severity of Illness Index; D018487:Ventricular Dysfunction, Left; D016277:Ventricular Function, Left